---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-020417"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:57:31.163715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evofem signs exclusive 5-year distributorship for SOLOSEC in sub-Saharan Africa with Clovis Davis

## Summary
- Exclusive 5-year distribution agreement with Clovis Davis for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.
- SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
- Clovis Davis to lead distribution, promotion, and sales; regulatory filings based on US FDA dossier.
- BV affects ~25% of women in sub-Saharan Africa; 10.9M women eligible in Ethiopia alone.
- No upfront payments or financial terms disclosed; partnership aims to expand global reach.

## SEC filing metadata
- accession: 0001493152-26-020417
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-020417
- JSON: https://secwatch.observer/filing/0001493152-26-020417.json
- Plain text: https://secwatch.observer/filing/0001493152-26-020417.txt

## Source-grounded claims
- claim_id: 9733ef1e5bfded64f48a31cad5709a3d17ddf7d4
  claim: Evofem Biosciences, Inc. entered into Distributorship Agreement with Clovis Davis Pharmaceuticals, LLC. (effective 2026-04-24).
  evidence_excerpt: On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.